APO Research
Talk to an analyst

APO RESEARCH · REPORT

Microbiome CDMO

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Microbiome CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

1 January 2026190 pages

Choose your research edition.

Industry ResearchMicrobiome CDMO Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Microbiome CDMO Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Microbiome CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Microbiome CDMO Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Microbiome CDMO Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Microbiome CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Microbiome CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Microbiome CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Microbiome CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Microbiome CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Microbiome CDMO include Arranta Bio, Wacker Chemie AG, Bactera, SGS Quay Pharma, Biose, EnteroBiotix, Genome And Company, Lallemand Health Solutions and List Bio, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Microbiome CDMO market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Microbiome CDMO and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Microbiome CDMO revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Microbiome CDMO market size, projected growth trends, production technologies, key applications, and end-use industries.

Microbiome CDMO Segment by Company

Arranta Bio

Wacker Chemie AG

Bactera

SGS Quay Pharma

Biose

EnteroBiotix

Genome And Company

Lallemand Health Solutions

List Bio

Rise BioServices

Lonza

MaaT Pharma

NIZO

Quay Pharmaceuticals

Recipharm

Microbiome CDMO Segment by Type

Microbial CDMO

Antibiotic CDMO

Phage CDMO

Bacteriocins CDMO

Microbiome CDMO Segment by Application

Vaccine R&D

Biopharmaceutical

Cell Therapy

Others

Microbiome CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbiome CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Microbiome CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbiome CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Microbiome CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Microbiome CDMO industry.

Chapter 3: Detailed analysis of Microbiome CDMO companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Microbiome CDMOrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Microbiome CDMO Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Microbial CDMO Table 3. Key Players of Antibiotic CDMO Table 4. Key Players of Phage CDMO Table 3. Key Players of Bacteriocins CDMO Table 4. Global Microbiome CDMO Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Vaccine R&D Table 6. Key Players of Biopharmaceutical Table 7. Key Players of Cell Therapy Table 8. Key Players of Others Table 9. Global Microbiome CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 10. Global Microbiome CDMO Market Size by Region (2021-2026) & (US$ Million) Table 11. Global Microbiome CDMO Market Share by Region (2021-2026) Table 12. Global Microbiome CDMO Market Size by Region (2027-2032) & (US$ Million) Table 13. Global Microbiome CDMO Market Share by Region (2027-2032) Table 14. Microbiome CDMO Industry Trends Table 15. Microbiome CDMO Industry Drivers Table 16. Microbiome CDMO Industry Opportunities and Challenges Table 17. Microbiome CDMO Industry Restraints Table 18. Global Microbiome CDMO Revenue by Company (US$ Million) & (2021-2026) Table 19. Global Microbiome CDMO Revenue Market Share by Company (2021-2026) Table 20. Global Microbiome CDMO Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 21. Global Microbiome CDMO Key Company Head Office and Area Served Table 22. Global Microbiome CDMO Company, Product Type & Application Table 23. Global Microbiome CDMO Company Establishment Date Table 24. Global Company Market Concentration Ratio (CR5 and HHI) Table 25. Global Microbiome CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 26. Global Microbiome CDMO Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Microbiome CDMO Market Size by Type (2021-2026) & (US$ Million) Table 28. Global Microbiome CDMO Market Size by Type (2027-2032) & (US$ Million) Table 29. Global Microbiome CDMO Revenue Market Share by Type (2021-2026) Table 30. Global Microbiome CDMO Revenue Market Share by Type (2027-2032) Table 31. Global Microbiome CDMO Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Microbiome CDMO Market Size by Application (2021-2026) & (US$ Million) Table 33. Global Microbiome CDMO Market Size by Application (2027-2032) & (US$ Million) Table 34. Global Microbiome CDMO Revenue Market Share by Application (2021-2026) Table 35. Global Microbiome CDMO Revenue Market Share by Application (2027-2032) Table 36. Arranta Bio Company Information Table 37. Arranta Bio Business Overview Table 38. Arranta Bio Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Arranta Bio Microbiome CDMO Product Portfolio Table 40. Arranta Bio Recent Development Table 41. Wacker Chemie AG Company Information Table 42. Wacker Chemie AG Business Overview Table 43. Wacker Chemie AG Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Wacker Chemie AG Microbiome CDMO Product Portfolio Table 45. Wacker Chemie AG Recent Development Table 46. Bactera Company Information Table 47. Bactera Business Overview Table 48. Bactera Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Bactera Microbiome CDMO Product Portfolio Table 50. Bactera Recent Development Table 51. SGS Quay Pharma Company Information Table 52. SGS Quay Pharma Business Overview Table 53. SGS Quay Pharma Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. SGS Quay Pharma Microbiome CDMO Product Portfolio Table 55. SGS Quay Pharma Recent Development Table 56. Biose Company Information Table 57. Biose Business Overview Table 58. Biose Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Biose Microbiome CDMO Product Portfolio Table 60. Biose Recent Development Table 61. EnteroBiotix Company Information Table 62. EnteroBiotix Business Overview Table 63. EnteroBiotix Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. EnteroBiotix Microbiome CDMO Product Portfolio Table 65. EnteroBiotix Recent Development Table 66. Genome And Company Company Information Table 67. Genome And Company Business Overview Table 68. Genome And Company Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Genome And Company Microbiome CDMO Product Portfolio Table 70. Genome And Company Recent Development Table 71. Lallemand Health Solutions Company Information Table 72. Lallemand Health Solutions Business Overview Table 73. Lallemand Health Solutions Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Lallemand Health Solutions Microbiome CDMO Product Portfolio Table 75. Lallemand Health Solutions Recent Development Table 76. List Bio Company Information Table 77. List Bio Business Overview Table 78. List Bio Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. List Bio Microbiome CDMO Product Portfolio Table 80. List Bio Recent Development Table 81. Rise BioServices Company Information Table 82. Rise BioServices Business Overview Table 83. Rise BioServices Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Rise BioServices Microbiome CDMO Product Portfolio Table 85. Rise BioServices Recent Development Table 86. Lonza Company Information Table 87. Lonza Business Overview Table 88. Lonza Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 89. Lonza Microbiome CDMO Product Portfolio Table 90. Lonza Recent Development Table 91. MaaT Pharma Company Information Table 92. MaaT Pharma Business Overview Table 93. MaaT Pharma Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 94. MaaT Pharma Microbiome CDMO Product Portfolio Table 95. MaaT Pharma Recent Development Table 96. NIZO Company Information Table 97. NIZO Business Overview Table 98. NIZO Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 99. NIZO Microbiome CDMO Product Portfolio Table 100. NIZO Recent Development Table 101. Quay Pharmaceuticals Company Information Table 102. Quay Pharmaceuticals Business Overview Table 103. Quay Pharmaceuticals Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 104. Quay Pharmaceuticals Microbiome CDMO Product Portfolio Table 105. Quay Pharmaceuticals Recent Development Table 106. Recipharm Company Information Table 107. Recipharm Business Overview Table 108. Recipharm Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 109. Recipharm Microbiome CDMO Product Portfolio Table 110. Recipharm Recent Development Table 111. North America Microbiome CDMO Market Size by Type (2021-2026) & (US$ Million) Table 112. North America Microbiome CDMO Market Size by Type (2027-2032) & (US$ Million) Table 113. North America Microbiome CDMO Market Size by Application (2021-2026) & (US$ Million) Table 114. North America Microbiome CDMO Market Size by Application (2027-2032) & (US$ Million) Table 115. North America Microbiome CDMO Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 116. North America Microbiome CDMO Market Size by Country (2021-2026) Table 117. North America Microbiome CDMO Market Size by Country (2027-2032) Table 118. Europe Microbiome CDMO Market Size by Type (2021-2026) & (US$ Million) Table 119. Europe Microbiome CDMO Market Size by Type (2027-2032) & (US$ Million) Table 120. Europe Microbiome CDMO Market Size by Application (2021-2026) & (US$ Million) Table 121. Europe Microbiome CDMO Market Size by Application (2027-2032) & (US$ Million) Table 122. Europe Microbiome CDMO Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 123. Europe Microbiome CDMO Market Size by Country (2021-2026) Table 124. Europe Microbiome CDMO Market Size by Country (2027-2032) Table 125. China Microbiome CDMO Market Size by Type (2021-2026) & (US$ Million) Table 126. China Microbiome CDMO Market Size by Type (2027-2032) & (US$ Million) Table 127. China Microbiome CDMO Market Size by Application (2021-2026) & (US$ Million) Table 128. China Microbiome CDMO Market Size by Application (2027-2032) & (US$ Million) Table 129. Asia Microbiome CDMO Market Size by Type (2021-2026) & (US$ Million) Table 130. Asia Microbiome CDMO Market Size by Type (2027-2032) & (US$ Million) Table 131. Asia Microbiome CDMO Market Size by Application (2021-2026) & (US$ Million) Table 132. Asia Microbiome CDMO Market Size by Application (2027-2032) & (US$ Million) Table 133. Asia Microbiome CDMO Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 134. Asia Microbiome CDMO Market Size by Country (2021-2026) Table 135. Asia Microbiome CDMO Market Size by Country (2027-2032) Table 136. South America, Middle East & Africa Microbiome CDMO Market Size by Type (2021-2026) & (US$ Million) Table 137. South America, Middle East & Africa Microbiome CDMO Market Size by Type (2027-2032) & (US$ Million) Table 138. South America, Middle East & Africa Microbiome CDMO Market Size by Application (2021-2026) & (US$ Million) Table 139. South America, Middle East & Africa Microbiome CDMO Market Size by Application (2027-2032) & (US$ Million) Table 140. South America, Middle East & Africa Microbiome CDMO Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 141. South America, Middle East & Africa Microbiome CDMO Market Size by Country (2021-2026) Table 142. South America, Middle East & Africa Microbiome CDMO Market Size by Country (2027-2032) Table 143. Research Programs/Design for This Report Table 144. Authors List of This Report Table 145. Secondary Sources Table 146. Primary Sources List of Figures Figure 1. Microbiome CDMO Product Image Figure 2. Global Microbiome CDMO Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Microbiome CDMO Market Share by Type: 2025 VS 2032 Figure 4. Microbial CDMO Image Figure 5. Antibiotic CDMO Image Figure 6. Phage CDMO Image Figure 7. Bacteriocins CDMO Image Figure 8. Global Microbiome CDMO Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 9. Global Microbiome CDMO Market Share by Application: 2025 VS 2032 Figure 10. Vaccine R&D Image Figure 11. Biopharmaceutical Image Figure 12. Cell Therapy Image Figure 13. Others Image Figure 14. Global Microbiome CDMO Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Microbiome CDMO Market Size (2021-2032) & (US$ Million) Figure 16. Global Microbiome CDMO Market Share by Region: 2025 VS 2032 Figure 17. Years Considered Figure 18. Global Microbiome CDMO Market Share by Players in 2025 Figure 19. Global Top 5 and 10 Microbiome CDMO Players Market Share by Revenue in 2025 Figure 20. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Microbiome CDMO Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Microbiome CDMO Revenue Market Share by Type (2021-2032) Figure 23. Global Microbiome CDMO Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Microbiome CDMO Revenue Market Share by Application (2021-2032) Figure 25. North America Microbiome CDMO Market Size (2021-2032) & (US$ Million) Figure 26. North America Microbiome CDMO Market Share by Type (2021-2032) Figure 27. North America Microbiome CDMO Market Share by Application (2021-2032) Figure 28. North America Microbiome CDMO Market Share by Country (2021-2032) Figure 29. United States Microbiome CDMO Market Size (2021-2032) & (US$ Million) Figure 30. Canada Microbiome CDMO Market Size (2021-2032) & (US$ Million) Figure 31. Mexico Microbiome CDMO Market Size (2021-2032) & (US$ Million) Figure 32. Europe Microbiome CDMO Market Size (2021-2032) & (US$ Million) Figure 33. Europe Microbiome CDMO Market Share by Type (2021-2032) Figure 34. Europe Microbiome CDMO Market Share by Application (2021-2032) Figure 35. Europe Microbiome CDMO Market Share by Country (2021-2032) Figure 36. Germany Microbiome CDMO Market Size (2021-2032) & (US$ Million) Figure 37. France Microbiome CDMO Market Size (2021-2032) & (US$ Million) Figure 38. U.K. Microbiome CDMO Market Size (2021-2032) & (US$ Million) Figure 39. Italy Microbiome CDMO Market Size (2021-2032) & (US$ Million) Figure 40. Russia Microbiome CDMO Market Size (2021-2032) & (US$ Million) Figure 41. Nordic Countries Microbiome CDMO Market Size (2021-2032) & (US$ Million) Figure 42. China Microbiome CDMO Market Size (2021-2032) & (US$ Million) Figure 43. China Microbiome CDMO Market Share by Type (2021-2032) Figure 44. China Microbiome CDMO Market Share by Application (2021-2032) Figure 45. Asia Microbiome CDMO Market Size (2021-2032) & (US$ Million) Figure 46. Asia Microbiome CDMO Market Share by Type (2021-2032) Figure 47. Asia Microbiome CDMO Market Share by Application (2021-2032) Figure 48. Asia Microbiome CDMO Market Share by Country (2021-2032) Figure 49. Japan Microbiome CDMO Market Size (2021-2032) & (US$ Million) Figure 50. South Korea Microbiome CDMO Market Size (2021-2032) & (US$ Million) Figure 51. Taiwan Microbiome CDMO Market Size (2021-2032) & (US$ Million) Figure 52. Southeast Asia Microbiome CDMO Market Size (2021-2032) & (US$ Million) Figure 53. India Microbiome CDMO Market Size (2021-2032) & (US$ Million) Figure 54. Australia Microbiome CDMO Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa Microbiome CDMO Market Size (2021-2032) & (US$ Million) Figure 56. South America, Middle East & Africa Microbiome CDMO Market Share by Type (2021-2032) Figure 57. South America, Middle East & Africa Microbiome CDMO Market Share by Application (2021-2032) Figure 58. South America, Middle East & Africa Microbiome CDMO Market Share by Country (2021-2032) Figure 59. Brazil Microbiome CDMO Market Size (2021-2032) & (US$ Million) Figure 60. South Africa Microbiome CDMO Market Size (2021-2032) & (US$ Million) Figure 61. Saudi Arabia Microbiome CDMO Market Size (2021-2032) & (US$ Million) Figure 62. Turkey Microbiome CDMO Market Size (2021-2032) & (US$ Million) Figure 63. Argentina Microbiome CDMO Market Size (2021-2032) & (US$ Million) Figure 64. UAE Microbiome CDMO Market Size (2021-2032) & (US$ Million) Figure 65. Egypt Microbiome CDMO Market Size (2021-2032) & (US$ Million) Figure 66. Chile Microbiome CDMO Market Size (2021-2032) & (US$ Million) Figure 67. Research Process Figure 68. Key Executives Interviewed

Scope & coverage.

Types
  • Microbial CDMO
  • Antibiotic CDMO
  • Phage CDMO
  • Bacteriocins CDMO
Applications
  • Vaccine R&D
  • Biopharmaceutical
  • Cell Therapy
  • Others
Companies covered
  • Arranta Bio
  • Wacker Chemie AG
  • Bactera
  • SGS Quay Pharma
  • Biose
  • EnteroBiotix
  • Genome And Company
  • Lallemand Health Solutions
  • List Bio
  • Rise BioServices
  • Lonza
  • MaaT Pharma
  • NIZO
  • Quay Pharmaceuticals
  • Recipharm

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Microbiome CDMO Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Microbial CDMO
  5. 1.2.3 Antibiotic CDMO
  6. 1.2.4 Phage CDMO
  7. 1.2.5 Bacteriocins CDMO
  8. 1.3 Market Analysis by Application
  9. 1.3.1 Global Microbiome CDMO Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  10. 1.3.2 Vaccine R&D
  11. 1.3.3 Biopharmaceutical
  12. 1.3.4 Cell Therapy
  13. 1.3.5 Others
  14. 1.4 Global Market Growth Prospects
  15. 1.5 Global Microbiome CDMO Growth Trends by Region
  16. 1.5.1 Global Microbiome CDMO Market Size by Region: 2021 VS 2025 VS 2032
  17. 1.5.2 Microbiome CDMO Market Size by Region (2021-2026)
  18. 1.5.3 Microbiome CDMO Market Size by Region (2027-2032)
  19. 1.6 Assumptions and Limitations
  20. 1.7 Study Goals and Objectives
  21. 1.8 Years Considered
2 Global Microbiome CDMO Market Dynamics
  1. 2.1 Microbiome CDMO Industry Trends
  2. 2.2 Microbiome CDMO Industry Drivers
  3. 2.3 Microbiome CDMO Industry Opportunities and Challenges
  4. 2.4 Microbiome CDMO Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Microbiome CDMO Revenue by Company (2021-2026)
  2. 3.2 Global Microbiome CDMO Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Microbiome CDMO Key Company Head office and Area Served
  4. 3.4 Global Microbiome CDMO Company, Product Type & Application
  5. 3.5 Global Microbiome CDMO Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Microbiome CDMO Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Microbiome CDMO Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Microbiome CDMO Tier 1, Tier 2, and Tier 3
4 Microbiome CDMO Market by Type
  1. 4.1 Global Microbiome CDMO Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Microbiome CDMO Market Size by Type (2021-2032)
  3. 4.3 Global Microbiome CDMO Market Size Share by Type (2021-2032)
5 Microbiome CDMO Market by Application
  1. 5.1 Global Microbiome CDMO Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Microbiome CDMO Market Size by Application (2021-2032)
  3. 5.3 Global Microbiome CDMO Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Arranta Bio
  2. 6.1.1 Arranta Bio Company Information
  3. 6.1.2 Arranta Bio Business Overview
  4. 6.1.3 Arranta Bio Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Arranta Bio Microbiome CDMO Product Portfolio
  6. 6.1.5 Arranta Bio Recent Developments
  7. 6.2 Wacker Chemie AG
  8. 6.2.1 Wacker Chemie AG Company Information
  9. 6.2.2 Wacker Chemie AG Business Overview
  10. 6.2.3 Wacker Chemie AG Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Wacker Chemie AG Microbiome CDMO Product Portfolio
  12. 6.2.5 Wacker Chemie AG Recent Developments
  13. 6.3 Bactera
  14. 6.3.1 Bactera Company Information
  15. 6.3.2 Bactera Business Overview
  16. 6.3.3 Bactera Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Bactera Microbiome CDMO Product Portfolio
  18. 6.3.5 Bactera Recent Developments
  19. 6.4 SGS Quay Pharma
  20. 6.4.1 SGS Quay Pharma Company Information
  21. 6.4.2 SGS Quay Pharma Business Overview
  22. 6.4.3 SGS Quay Pharma Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 SGS Quay Pharma Microbiome CDMO Product Portfolio
  24. 6.4.5 SGS Quay Pharma Recent Developments
  25. 6.5 Biose
  26. 6.5.1 Biose Company Information
  27. 6.5.2 Biose Business Overview
  28. 6.5.3 Biose Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Biose Microbiome CDMO Product Portfolio
  30. 6.5.5 Biose Recent Developments
  31. 6.6 EnteroBiotix
  32. 6.6.1 EnteroBiotix Company Information
  33. 6.6.2 EnteroBiotix Business Overview
  34. 6.6.3 EnteroBiotix Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 EnteroBiotix Microbiome CDMO Product Portfolio
  36. 6.6.5 EnteroBiotix Recent Developments
  37. 6.7 Genome And Company
  38. 6.7.1 Genome And Company Company Information
  39. 6.7.2 Genome And Company Business Overview
  40. 6.7.3 Genome And Company Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Genome And Company Microbiome CDMO Product Portfolio
  42. 6.7.5 Genome And Company Recent Developments
  43. 6.8 Lallemand Health Solutions
  44. 6.8.1 Lallemand Health Solutions Company Information
  45. 6.8.2 Lallemand Health Solutions Business Overview
  46. 6.8.3 Lallemand Health Solutions Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Lallemand Health Solutions Microbiome CDMO Product Portfolio
  48. 6.8.5 Lallemand Health Solutions Recent Developments
  49. 6.9 List Bio
  50. 6.9.1 List Bio Company Information
  51. 6.9.2 List Bio Business Overview
  52. 6.9.3 List Bio Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 List Bio Microbiome CDMO Product Portfolio
  54. 6.9.5 List Bio Recent Developments
  55. 6.10 Rise BioServices
  56. 6.10.1 Rise BioServices Company Information
  57. 6.10.2 Rise BioServices Business Overview
  58. 6.10.3 Rise BioServices Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Rise BioServices Microbiome CDMO Product Portfolio
  60. 6.10.5 Rise BioServices Recent Developments
  61. 6.11 Lonza
  62. 6.11.1 Lonza Company Information
  63. 6.11.2 Lonza Business Overview
  64. 6.11.3 Lonza Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Lonza Microbiome CDMO Product Portfolio
  66. 6.11.5 Lonza Recent Developments
  67. 6.12 MaaT Pharma
  68. 6.12.1 MaaT Pharma Company Information
  69. 6.12.2 MaaT Pharma Business Overview
  70. 6.12.3 MaaT Pharma Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 MaaT Pharma Microbiome CDMO Product Portfolio
  72. 6.12.5 MaaT Pharma Recent Developments
  73. 6.13 NIZO
  74. 6.13.1 NIZO Company Information
  75. 6.13.2 NIZO Business Overview
  76. 6.13.3 NIZO Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 NIZO Microbiome CDMO Product Portfolio
  78. 6.13.5 NIZO Recent Developments
  79. 6.14 Quay Pharmaceuticals
  80. 6.14.1 Quay Pharmaceuticals Company Information
  81. 6.14.2 Quay Pharmaceuticals Business Overview
  82. 6.14.3 Quay Pharmaceuticals Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Quay Pharmaceuticals Microbiome CDMO Product Portfolio
  84. 6.14.5 Quay Pharmaceuticals Recent Developments
  85. 6.15 Recipharm
  86. 6.15.1 Recipharm Company Information
  87. 6.15.2 Recipharm Business Overview
  88. 6.15.3 Recipharm Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 Recipharm Microbiome CDMO Product Portfolio
  90. 6.15.5 Recipharm Recent Developments
7 North America
  1. 7.1 North America Microbiome CDMO Market Size (2021-2032)
  2. 7.2 North America Microbiome CDMO Market Size by Type
  3. 7.2.1 North America Microbiome CDMO Market Size by Type (2021-2026)
  4. 7.2.2 North America Microbiome CDMO Market Size by Type (2027-2032)
  5. 7.2.3 North America Microbiome CDMO Market Share by Type (2021-2032)
  6. 7.3 North America Microbiome CDMO Market Size by Application
  7. 7.3.1 North America Microbiome CDMO Market Size by Application (2021-2026)
  8. 7.3.2 North America Microbiome CDMO Market Size by Application (2027-2032)
  9. 7.3.3 North America Microbiome CDMO Market Share by Application (2021-2032)
  10. 7.4 North America Microbiome CDMO Market Size by Country
  11. 7.4.1 North America Microbiome CDMO Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Microbiome CDMO Market Size by Country (2021-2026)
  13. 7.4.3 North America Microbiome CDMO Market Size by Country (2027-2032)
  14. 7.4.4 North America Microbiome CDMO Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Microbiome CDMO Market Size (2021-2032)
  2. 8.2 Europe Microbiome CDMO Market Size by Type
  3. 8.2.1 Europe Microbiome CDMO Market Size by Type (2021-2026)
  4. 8.2.2 Europe Microbiome CDMO Market Size by Type (2027-2032)
  5. 8.2.3 Europe Microbiome CDMO Market Share by Type (2021-2032)
  6. 8.3 Europe Microbiome CDMO Market Size by Application
  7. 8.3.1 Europe Microbiome CDMO Market Size by Application (2021-2026)
  8. 8.3.2 Europe Microbiome CDMO Market Size by Application (2027-2032)
  9. 8.3.3 Europe Microbiome CDMO Market Share by Application (2021-2032)
  10. 8.4 Europe Microbiome CDMO Market Size by Country
  11. 8.4.1 Europe Microbiome CDMO Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Microbiome CDMO Market Size by Country (2021-2026)
  13. 8.4.3 Europe Microbiome CDMO Market Size by Country (2027-2032)
  14. 8.4.4 Europe Microbiome CDMO Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Microbiome CDMO Market Size (2021-2032)
  2. 9.2 China Microbiome CDMO Market Size by Type
  3. 9.2.1 China Microbiome CDMO Market Size by Type (2021-2026)
  4. 9.2.2 China Microbiome CDMO Market Size by Type (2027-2032)
  5. 9.2.3 China Microbiome CDMO Market Share by Type (2021-2032)
  6. 9.3 China Microbiome CDMO Market Size by Application
  7. 9.3.1 China Microbiome CDMO Market Size by Application (2021-2026)
  8. 9.3.2 China Microbiome CDMO Market Size by Application (2027-2032)
  9. 9.3.3 China Microbiome CDMO Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Microbiome CDMO Market Size (2021-2032)
  2. 10.2 Asia Microbiome CDMO Market Size by Type
  3. 10.2.1 Asia Microbiome CDMO Market Size by Type (2021-2026)
  4. 10.2.2 Asia Microbiome CDMO Market Size by Type (2027-2032)
  5. 10.2.3 Asia Microbiome CDMO Market Share by Type (2021-2032)
  6. 10.3 Asia Microbiome CDMO Market Size by Application
  7. 10.3.1 Asia Microbiome CDMO Market Size by Application (2021-2026)
  8. 10.3.2 Asia Microbiome CDMO Market Size by Application (2027-2032)
  9. 10.3.3 Asia Microbiome CDMO Market Share by Application (2021-2032)
  10. 10.4 Asia Microbiome CDMO Market Size by Country
  11. 10.4.1 Asia Microbiome CDMO Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Microbiome CDMO Market Size by Country (2021-2026)
  13. 10.4.3 Asia Microbiome CDMO Market Size by Country (2027-2032)
  14. 10.4.4 Asia Microbiome CDMO Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Microbiome CDMO Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Microbiome CDMO Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Microbiome CDMO Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Microbiome CDMO Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Microbiome CDMO Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Microbiome CDMO Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Microbiome CDMO Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Microbiome CDMO Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Microbiome CDMO Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Microbiome CDMO Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Microbiome CDMO Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Microbiome CDMO Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Microbiome CDMO Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Microbiome CDMO Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst